Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Alex Shimmings
Johnson & Johnson has suspended Phase IIb trial of its RSV asset written off a further $700m against its RSV candidate that it obtained with its $1.75bn purchase of Alios.
As its lead product fails at Phase IIb in diabetic retinopathy, Aerpio’s attentions turn to its other potential indications, but investors will need more convincing that this strategy will pay dividends.
A strong immunological response to the PQ Birch vaccine did not translate into any appreciable reduction in symptoms in the Phase III trial, leaving the UK firm perplexed, and its share price southwards.
Galderma’s novel biologic is heading for Phase III studies in moderate-to-severe atopic dermatitis as the race to join Dupixent in an expanding market hots up.
A decision to yoke together two indications in one EU accelerated assessment filing for the anticancer has backfired on Roche and left the product at even more of a disadvantage compared with Bayer’s Vitrakvi in the tumor-agnostic setting.
Novavax’s shares plunged 67% on news that its Phase III trial for RSV had failed, but are there signs of life for the product?